Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study
Authors:
Open Access
- 2 March 2023
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (1) , 36-44
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim International GmbH
- Boehringer Ingelheim
This publication has 15 references indexed in Scilit:
- Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasisJournal of Allergy and Clinical Immunology, 2022
- Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareBMJ Open, 2021
- New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infectionDermatologic Therapy, 2020
- Biologics in the treatment of pustular psoriasisExpert Opinion on Drug Safety, 2020
- Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPPThe Journal of Dermatology, 2018
- Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label studyThe Journal of Dermatology, 2018
- Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)The Journal of Dermatology, 2016
- Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label studyBritish Journal of Dermatology, 2016
- Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese studyThe Journal of Dermatology, 2016
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular PsoriasisNew England Journal of Medicine, 2011